|
BLTP3A (also known as UHRF1BP1) silenced CAR-T cells demonstrate elevated efficacy against High-grade serous carcinoma (HGSC)
Impairing BLTP3A elevates T cells activity via enhanced recycling of TCR and CAR machinery through the endosomal system.
Invention Summary:
Despite recent advances in cancer immunotherapy, objective responses remain rare. This is partly due to an incomplete understanding of the complex immunosuppressive mechanisms operating within the...
Published: 2/21/2025
|
Inventor(s): Kyle Payne, Fnu Kumari
Keywords(s):
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Therapeutics, Technology Classifications > Cell Therapy
|
|
Repurposing H1 and H2 antihistamines for the treatment of erythropoietic protoporphyria
Invention Summary:
Erythropoietic protoporphyria (EPP) is a severe genetic disorder caused by defects in heme biosynthesis, leading to the accumulation of protoporphyrin IX (PP-IX) in the liver. This accumulation results in cholestasis and, in the most severe cases, end-stage liver failure, necessitating liver transplantation or leading to...
Published: 2/4/2025
|
Inventor(s): Bishr Omary, Ning Kuo
Keywords(s):
Category(s): Technology Classifications > Therapeutics, Technology Classifications > Rare Disease
|
|
Treatments for tuberculosis and non-tuberculous mycobacterial infections: dual-targeted rifamycin-AAP conjugates (RifaAAPs)
collapse; }
Invention Summary:
RifaAAPs are novel dual-targeted, low-resistance-emergence, orally-available compounds for treatment of tuberculosis (TB) and non-tuberculous mycobacterial (NTM) infections--including drug-resistant, multi-drug-resistant (MDR), and extensively-drug-resistant (XDR) strains.
Researchers indicate that...
Published: 1/31/2025
|
Inventor(s): Richard Ebright, Yon Ebright, Chih-Tsung Lin
Keywords(s): Antibacterial
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Therapeutics
|
|
ANTIBACTERIAL AGENTS: CO-SOLVENT-FREE, SURFACTANT-FREE FORMULATIONS OF PYRONINS
Invention Summary:
APYs are novel, orally available compounds for treatment of infections caused by Gram-positive bacterial pathogens, fastidious Gram-negative bacterial pathogens, and some non-fastidious Gram-negative bacterial pathogens--including drug-resistant and multi-drug-resistant (MDR) strains.
Our researchers have indicated...
Published: 1/31/2025
|
Inventor(s): Richard Ebright, Yon Ebright
Keywords(s): Antibacterial
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Therapeutics
|
|
ANTIBACTERIAL AGENTS: O-ALKYL-DEUTERATED PYRONINS (PYS) AND ARYL PYRONINS (APYS)
Invention Summary:
APYs are novel, orally available compounds for treatment of infections caused by Gram-positive bacterial pathogens, fastidious Gram-negative bacterial pathogens, and some non-fastidious Gram-negative bacterial pathogens--including drug-resistant and multi-drug-resistant (MDR) strains.
Our researchers have indicated...
Published: 1/31/2025
|
Inventor(s): Richard Ebright, Yon Ebright
Keywords(s): Antibacterial
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Therapeutics
|
|
Microglia Cell Therapy for the Treatment of Neurodegenerative Diseases
Human Microglia
Invention Summary:
Alzheimer’s Disease (AD) accounts for over 60% of dementia cases in people over 65. Individuals with Down Syndrome (DS) are at higher risk for AD and myeloid leukemia due to somatic mutations in hematopoietic cells. Interestingly, some DS individuals with AD neuropathology do not experience cognitive...
Published: 1/31/2025
|
Inventor(s): Peng Jiang, Mengmeng Jin
Keywords(s): Neurological disorder & neuropathic pain
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Therapeutics
|
|
Photolabile Sulfinate Protecting Groups for SuFEx synthesis of sulfonyl fluorides, sulfonamides, and sulfones with applications in drug discovery and manufacture
Photo-labile SPGs protect sulfur-containing compounds in cross-coupling, acidic, and basic conditions. SPGs will convert to sulfonyl fluoride upon light exposure (See preprint below).
Invention Summary:
Sulfur-derived functional groups such as sulfonyl fluorides, sulfonamides, and sulfones have a significant role in the synthesis of complex...
Published: 1/30/2025
|
Inventor(s): Matthew Moschitto, Twinkle Patel, Ramkrishna Laha
Keywords(s):
Category(s): Technology Classifications > Therapeutics
|
|
Enterovirus D68 capsid inhibitors as antivirals
Plaque assay results of Jun11-46-1 and Jun11-54-1 against EV-D68 US/MO/14-18947.
Invention Summary:
Enterovirus D68 (EV-D68) is an RNA virus that mainly affects children and results in moderate to severe respiratory illness, with the most extreme cases resulting in muscle weakness, paralysis, and death. Currently, there are no antivirals...
Published: 1/27/2025
|
Inventor(s): Jun Wang, Yanmei Hu, Kan Li
Keywords(s): Antibacterial, Small molecules
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Infectious Disease, Technology Classifications > Therapeutics
|
|
Small Molecule Direct Inhibitors of Keap1-Nrf2 Protein-Protein Interaction
Non-covalent direct inhibition of the Keap1-Nrf2 PPI resulting in upregulation of ARE-gene expression. Thus, increase ARE-controlled cytoprotective oxidative stress response enzymes in the development of therapeutic and preventive agents for a number of diseases and conditions.
Invention Summary:
The Keap1-Nrf2-ARE system could protect...
Published: 1/14/2025
|
Inventor(s): Longqin Hu, Ahmed Ali
Keywords(s):
Category(s): Technology Classifications > Therapeutics, Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Cancer
|
|
Identification of NFAT5 as a novel target for preventing KRAS targeted therapy resistance
Inhibiting NFAT5 attenuates pancreatitis-induced resistance to KRAS inhibition and extends mouse survival.
Invention Summary:
Resistance to KRAS targeted therapy in cancers involves epithelial-to-mesenchymal transition (EMT), which poses challenges for effective targeting. However, the mechanism underlying EMT associated KRAS resistance...
Published: 1/6/2025
|
Inventor(s): Pingping Hou, Daiyong Deng
Keywords(s): Anti-cancer
Category(s): Technology Classifications > Cancer, Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Therapeutics
|
